Vaxcyte, Inc.
US ˙ NasdaqGS ˙ US92243G1085

SecurityPCVX / Vaxcyte, Inc.
InstitutionLazard Asset Management Llc
Latest Disclosed Ownership47,023 shares
Latest Disclosed Value $ 2,732,507
Lazard Asset Management Llc reports 27.63% decrease in ownership of PCVX / Vaxcyte, Inc.

On May 15, 2026 - Lazard Asset Management Llc filed a 13F-HR form disclosing ownership of 47,023 shares of Vaxcyte, Inc. (US:PCVX) valued at $2,732,507 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 64,978 shares of Vaxcyte, Inc.. This represents a change in shares of -27.63% during the quarter. The current value of the position is $2,227,009 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VAXCYTE COM 92243G108 47,023 -17,955 -27.63 2,733 -8.87 0.0023
2026-02-17 2025-12-31 13F VAXCYTE COM 92243G108 64,978 -54,114 -45.44 2,998 -30.10 0.0051
2025-11-14 2025-09-30 13F VAXCYTE COM 92243G108 119,092 -393,043 -76.75 4,290 26,706.25 0.0058
2025-08-14 2025-06-30 13F VAXCYTE Common Stock 92243G108 512,135 -45,659 -8.19 17 -23.81 0.0229
2025-05-15 2025-03-31 13F VAXCYTE Common Stock 92243G108 557,794 71,030 14.59 21 -46.15 0.0323
2025-02-14 2024-12-31 13F VAXCYTE Common Stock 92243G108 486,764 486,764 40 0.0583
2023-11-14 2023-09-30 13F VAXCYTE Common Stock 92243G108 0 -9,268 -100.00 0 0.0000
2023-08-15 2023-06-30 13F VAXCYTE Common Stock 92243G108 9,268 9,268 0 0.0006
2023-05-15 2023-03-31 13F VAXCYTE Common Stock 92243G108 0 -7,741 -100.00 0 -100.00
2023-02-15 2022-12-31 13F VAXCYTE Common Stock 92243G108 7,741 7,741 371 0.0005
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.